Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms
- 1 June 2017
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (12), 2689-2694
- https://doi.org/10.1016/j.bmcl.2017.04.042
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1Journal of Medicinal Chemistry, 2016
- An atomic model of HIV-1 capsid-SP1 reveals structures regulating assembly and maturationScience, 2016
- Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic CoverageAntimicrobial Agents and Chemotherapy, 2016
- Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 LatticeJournal of Virology, 2016
- Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage siteEuropean Journal of Medicinal Chemistry, 2013
- New Betulinic Acid Derivatives for Bevirimat-Resistant Human Immunodeficiency Virus Type-1Journal of Medicinal Chemistry, 2013
- Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation InhibitorsJournal of Medicinal Chemistry, 2012
- Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE StudyPLOS ONE, 2010
- Transmission of HIV‐1 Drug‐Resistant Variants: Prevalence and Effect on Treatment OutcomeClinical Infectious Diseases, 2010
- Novel approaches to inhibiting HIV-1 replicationAntiviral Research, 2010